Action Bristol Myers Squibb - BMY

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

61,55

Prix Achat

Prix Vente

Volume échangé

14 636 599

61,2277 Fourchette du Jour 63,33

39,35 Plage de 52 semaines 63,16

Cap du marché

124,904B

Clôture Veille

63,11

Ouverture

62,80

Dernière Transaction

61.73

Dernière heure de transaction

Volume financier

US$ 909 047 256

VWAP

62,1078

Volume moyen (3 m)

11 676 149

Actions en circulation

2 029 312 023

Rendement du Dividende

4.03%

Ratio Cours sur Bénéfices

-13,95

Bénéfice par action (BPA)

-4,41

Chiffre d'affairess

48,3B

Bénéfice net

-8,95B

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.bms.com

Siège social

Wilmington, Delaware, USA

Fondé

Bristol Myers Squibb Co est coté dans le secteur Pharmaceutical Preparations de la New York Stock Exchange avec le ticker BMY. Le dernier cours de clôture d'Bristol Myers Squibb était de US$63,11. Au cours de la dernière année, les actions de Bristol Myers Squibb ont été négociées dans une fourchette de prix de US$ 39,35 à US$ 63,16.

Bristol Myers Squibb compte actuellement 2 029 312 023 actions en circulation. La capitalisation boursière d'Bristol Myers Squibb est de US$128,07 milliard. Bristol Myers Squibb a un ratio cours/bénéfice (ratio PE) de -13.95.

Flux global

Haussier

Prime nette

4M

Calls / Puts

279,31%

Ach. / Vent.

271,43%

OTM / ITM

44,74%

Sweeps Ratio

0,00%

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc. PR Newswire NEW YORK, March 11, 2025 NEW YORK, March 11, 2025...

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free...

Form 4 - Statement of changes in beneficial ownership of securities

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which...

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile...

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the...

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate With these data, Breyanzi demonstrates...

Form 8-K - Current report

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+9...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.61	2.68601935269	59.94	63.16	59.03	15079847	60.97948704	CS
4	6.15	11.1010830325	55.4	63.16	53.54	12291070	58.26600799	CS
12	5.27	9.36389481166	56.28	63.16	53.54	11676149	57.7604449	CS
26	12.31	25	49.24	63.16	47.7635	11209246	55.96049448	CS
52	7.65	14.1929499072	53.9	63.16	39.35	13204792	50.21740701	CS
156	-6.54	-9.60493464532	68.09	81.435	39.35	11896223	59.70812128	CS
260	4.76	8.38175735165	56.79	81.435	39.35	11993597	60.40521186	CS

BMY - Frequently Asked Questions (FAQ)

What is the current Bristol Myers Squibb share price?

The current share price of Bristol Myers Squibb is US$ 61,55

How many Bristol Myers Squibb shares are in issue?

Bristol Myers Squibb has 2 029 312 023 shares in issue

What is the market cap of Bristol Myers Squibb?

The market capitalisation of Bristol Myers Squibb is USD 128,07B

What is the 1 year trading range for Bristol Myers Squibb share price?

Bristol Myers Squibb has traded in the range of US$ 39,35 to US$ 63,16 during the past year

What is the PE ratio of Bristol Myers Squibb?

The price to earnings ratio of Bristol Myers Squibb is -13,95

What is the cash to sales ratio of Bristol Myers Squibb?

The cash to sales ratio of Bristol Myers Squibb is 2,58

What is the reporting currency for Bristol Myers Squibb?

Bristol Myers Squibb reports financial results in USD

What is the latest annual turnover for Bristol Myers Squibb?

The latest annual turnover of Bristol Myers Squibb is USD 48,3B

What is the latest annual profit for Bristol Myers Squibb?

The latest annual profit of Bristol Myers Squibb is USD -8,95B

What is the registered address of Bristol Myers Squibb?

The registered address for Bristol Myers Squibb is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Bristol Myers Squibb website address?

The website address for Bristol Myers Squibb is www.bms.com

Which industry sector does Bristol Myers Squibb operate in?

Bristol Myers Squibb operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
PAYPaymentus Holdings Inc	US$ 30,95 (25,41%)	2,58M
EXKEndeavour Silver Corporation	US$ 4,52 (24,18%)	16,24M
HLLYHolley Inc	US$ 2,98 (24,17%)	1,44M
NUVBPanacea Acquisition Corp	US$ 2,295 (22,07%)	4,57M
ZKZEEKR Intelligent Technology Holding Limited	US$ 32,85 (18,51%)	1,44M
NPWRNET Power Inc	US$ 3,22 (-32,21%)	6,64M
ASANAsana Inc	US$ 12,64 (-24,22%)	19,03M
KSSKohls Corporation	US$ 9,15 (-24,07%)	50,32M
NOVASunnova Energy International Inc	US$ 0,4202 (-17,46%)	28,09M
KUKEKuke Music Holding Limited	US$ 0,2248 (-15,55%)	633,05k
FFord Motor Company	US$ 9,68 (-2,81%)	210,11M
NIONIO Inc	US$ 5,205 (16,70%)	162,15M
TAT&T Inc	US$ 26,01 (-4,66%)	74,57M
VZVerizon Communications Inc	US$ 43,43 (-6,58%)	64,14M
BBDBanco Bradesco SA	US$ 1,995 (-0,25%)	56,31M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bristol Myers Squibb Co (BMY) Cours

Bristol Myers Squibb Co (BMY)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Bristol Myers Squibb Co

Flux d'options Bristol Myers Squibb (BMY)

Flux global

Haussier

Prime nette

4M

Calls / Puts

279,31%

Ach. / Vent.

271,43%

OTM / ITM

44,74%

Sweeps Ratio

0,00%

BMY Dernières nouvelles

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Form 4 - Statement of changes in beneficial ownership of securities

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Form 8-K - Current report

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Form 4 - Statement of changes in beneficial ownership of securities

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Form 8-K - Current report

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

BMY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités